CSPC Pharmaceutical Group Receives FDA Approval for Clinical Trials of SYH2082 Injection

CSPC Pharmaceutical Group announced that its GLP-1/GIP receptor dual-biased agonist peptide long-acting injection, SYH2082, has received approval from the U.S. Food and Drug Administration (FDA) to conduct clinical trials in the United States. According to Jin10, the approved clinical indication is for weight management in individuals who are obese or overweight with at least one weight-related comorbidity. Additionally, SYH2082 has the potential to improve blood glucose control in adults with type 2 diabetes mellitus (T2DM), offering additional clinical benefits.